Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Aarkstore Enterprise - The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts

Posted Nov 18 2010 5:15am
Aarkstore announce a new report  "The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities" through its vast collection of market research report.

Summary

“The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets

Scope

The scope of this report includes:
- Annualized market data for the blood disorders market from 2001 to 2009, forecast forward to 2016
- Analysis of the leading therapeutic segments including anemia, thrombosis, hemophilia, neutropenia and thrombocytopenia
- Analysis of the blood disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the blood disorders market including market size, annual cost of therapy, sales volume and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Amgen, Inc., Sanofi-Aventis, Bristol-Myers Squibb, Centocor Ortho Biotech Inc., and Baxter.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global blood disorders market

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

For more information, please visit:
http://www.aarkstore.com/reports/The-Future-of-Blood-Disorders-Therapeutics-Anal
Or email us at press@aarkstore.com or call +919272852585
Post a comment
Write a comment:

Related Searches